Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Connect Biopharma Holdings Ltd ADR
(NQ:
CNTB
)
1.250
-0.010 (-0.79%)
Streaming Delayed Price
Updated: 1:26 PM EDT, Sep 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Connect Biopharma Holdings Ltd ADR
Connect Biopharma to Participate in the Cantor Fitzgerald Global Healthcare Conference 2024
September 10, 2024
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update
September 05, 2024
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
July 01, 2024
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 12, 2024
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Announces New Leadership and Chair of the Board of Directors
June 12, 2024
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma
May 22, 2024
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
May 07, 2024
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
April 16, 2024
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference
March 19, 2024
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
February 12, 2024
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
December 12, 2023
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023
December 11, 2023
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
November 30, 2023
Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to...
Via
Newsfile
Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China
November 21, 2023
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis
November 21, 2023
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023
November 20, 2023
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
September 12, 2023
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
September 12, 2023
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma to Participate in Upcoming September Investor Conferences
August 24, 2023
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology
July 10, 2023
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma to Participate in the SVB Securities Therapeutics Forum
July 05, 2023
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis
June 01, 2023
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business Update
April 11, 2023
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms
March 18, 2023
From
Connect Biopharma Holdings Limited
Via
Business Wire
Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions
March 17, 2023
From
Connect Biopharma Holdings Limited
Via
Business Wire
Connect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual Meeting
March 06, 2023
From
Connect Biopharma Holdings Limited
Via
Business Wire
Connect Biopharma To Present at Upcoming Investor and Scientific Conferences
October 27, 2022
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
CORRECTING and REPLACING -- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China
October 04, 2022
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China
October 04, 2022
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis
October 03, 2022
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.